Article info
Poster Presentation
Rheumatoid arthritis - anti-TNF therapy
FRI0184 Cost-effectiveness and budget impact of certolizumab pegol against the current mix of anti-tnf treatments in an outcomes-based risk-sharing scheme in finland
Citation
FRI0184 Cost-effectiveness and budget impact of certolizumab pegol against the current mix of anti-tnf treatments in an outcomes-based risk-sharing scheme in finland
Publication history
- First published January 23, 2014.
Online issue publication
January 23, 2014
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions